Fatty Liver News and Research

Latest Fatty Liver News and Research

Three ways to de-program the 1950s obesity trinity underlying current obesity epidemic

In a first person paper published in the August 27, 2010 issue of Childhood Obesity, Dr. Melinda Sothern, Director of Health Promotion and Professor of Public Health at LSU Health Sciences Center New Orleans, provides three ways to de-program the 1950s obesity trinity underlying the current obesity epidemic in the United States and protect future generations from its health consequences.

3 Sep 2010

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

In its review of the BLA, the FDA stated the T-DM1 trials did not meet the standard for accelerated approval because all available treatment choices approved for metastatic breast cancer, regardless of HER2 status, had not been exhausted in the study population.

27 Aug 2010

FDA extends review on Acetadote for non-acetaminophen acute liver failure

Cumberland Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration (FDA) has extended its review of the supplemental new drug application (sNDA) for the use of Acetadote® (acetylcysteine) Injection in patients with non-acetaminophen acute liver failure.

21 Aug 2010

Study links obesity rates with walking and cycling rates

A study authored by Professor David Bassett Jr. from the Department of Kinesiology, Recreation and Sport Studies at the University of Tennessee, Knoxville, and three other researchers was published in the American Journal of Public Health, concluding that communities with more walkers and cyclists are healthier than those where people must rely on cars to get around.

20 Aug 2010

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Researchers at Massachusetts General Hospital found that patients with nonalcoholic fatty liver disease (NAFLD) who carry an allele of the PNPLA3 gene have an increased risk of developing advanced disease, including nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. A second study supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) validates these findings and further concludes that in pediatric patients, the same allele is associated with earlier disease presentation.

18 Aug 2010

Research confirms genetic link to advanced fatty liver disease

17 Aug 2010

Study shows link between fructose and pancreatic cancer proliferation

Pancreatic cancers use the sugar fructose, very common in the Western diet, to activate a key cellular pathway that drives cell division, helping the cancer to grow more quickly, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

4 Aug 2010

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH).

28 Jul 2010

UDCA fails to improve overall histology in NASH patients: Study

A study conducted by researchers at Johann Wolfgang Goethe University in Frankfurt, Germany found that high doses of ursodeoxycholic acid, suggested by some studies to have a beneficial effect on nonalcoholic steatohepatitis, does not improve overall histology in these patients. Full findings of this study are published in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

21 Jul 2010

Early markers for metabolic syndrome in youth

Melinda Sothern, PhD, CEP, Professor of Public Health and Director of Health Promotion at LSU Health Sciences Center New Orleans, will present evidence that supports relationships seen in adolescents between insulin sensitivity and fatty liver, belly fat, and total body fat and identifies additional potential early markers of insulin resistance and metabolic syndrome in healthy 7-9 year-old children, including fat in muscle cells, blood pressure, physical activity, and birth weight.

13 Jul 2010

Research findings could offer new approach to diabetes therapy, nutrition experts say

Nutrition experts at Oregon State University have essentially "cured" laboratory mice of mild, diet-induced diabetes by stimulating the production of a particular enzyme. The findings could offer a new approach to diabetes therapy, experts say, especially if a drug could be identified that would do the same thing, which in this case was accomplished with genetic manipulation.

13 Jul 2010

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.

7 Jul 2010

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

24 Jun 2010

Diet with high fructose, trans fats lead to fatty liver disease with scar tissue

Scientists at Cincinnati Children's Hospital Medical Center have discovered that a diet with high levels of fructose - levels equivalent to that in high fructose corn syrup - and of trans fats not only increases obesity, but also leads to significant fatty liver disease with scar tissue.

23 Jun 2010

Drinking coffee may help prevent diabetes, report scientists

Scientists are reporting new evidence that drinking coffee may help prevent diabetes and that caffeine may be the ingredient largely responsible for this effect. Their findings, among the first animal studies to demonstrate this apparent link, appear in ACS' bi-weekly Journal of Agricultural and Food Chemistry.

10 Jun 2010

NASH-induced cirrhosis is greater risk factor for HCC: Cleveland Clinic study

A study conducted by researchers at the Cleveland Clinic finds that patients suffering from cirrhosis preceded by nonalcoholic steatohepatitis are at an equal risk of developing hepatocellular carcinoma than those who develop cirrhosis resulting from hepatitis C virus. Results of this study appear in the June issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

26 May 2010

Study identifies potential noninvasive biomarkers in NAFLD, NASH using Metabolon's platform

Metabolon, Inc. announces a study published in the Metabolism Journal released in the paper on April 28, 2010, by Satish C. Kalhan.

17 May 2010

Obesity epidemic may be flattening out - still much to be done

The prevalence of childhood obesity might be stabilising in developed countries, but there is still much to be done to combat this major threat to health, according to a Seminar published on Online First and in an upcoming issue of The Lancet.

6 May 2010

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Raptor Pharmaceutical Corp., announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis, a progressive form of liver disease believed to affect 5% to 11% of the U.S. population. The results were presented at the Digestive Disease Week 2010 conference in New Orleans, LA on May 2, 2010.

3 May 2010

Health outcomes explored at DDW 2010

Non-alcoholic fatty liver disease, which may soon be the leading indication for liver transplant, is found to be significantly associated with worse transplant outcomes. In addition, a new tool for diagnosing NAFLD represents an alternative to liver biopsy, which is more expensive and prone to complications, and ultrasound and alfafeprotein blood test screening are an effective alternative to CT scan and MRI for patients with cirrhosis at high risk for hepatocellular cancer.

3 May 2010

Fatty Liver News and Research

Latest Fatty Liver News and Research

Three ways to de-program the 1950s obesity trinity underlying current obesity epidemic

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

FDA extends review on Acetadote for non-acetaminophen acute liver failure

Study links obesity rates with walking and cycling rates

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Research confirms genetic link to advanced fatty liver disease

Study shows link between fructose and pancreatic cancer proliferation

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

UDCA fails to improve overall histology in NASH patients: Study

Early markers for metabolic syndrome in youth

Research findings could offer new approach to diabetes therapy, nutrition experts say

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Diet with high fructose, trans fats lead to fatty liver disease with scar tissue

Drinking coffee may help prevent diabetes, report scientists

NASH-induced cirrhosis is greater risk factor for HCC: Cleveland Clinic study

Study identifies potential noninvasive biomarkers in NAFLD, NASH using Metabolon's platform

Obesity epidemic may be flattening out - still much to be done

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Health outcomes explored at DDW 2010

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Fatty Liver News and Research

Latest Fatty Liver News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in